Vanguard Group Inc Has $20.92 Million Position in United Community Financial Corp (UCFC)

Vanguard Group Inc increased its stake in United Community Financial Corp (NASDAQ:UCFC) by 3.2% in the third quarter, according to the company …

United Community Financial logoVanguard Group Inc increased its stake in United Community Financial Corp (NASDAQ:UCFC) by 3.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,163,015 shares of the savings and loans company’s stock after buying an additional 67,397 shares during the quarter. Vanguard Group Inc owned about 4.35% of United Community Financial worth $20,915,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of UCFC. Private Advisor Group LLC bought a new stake in United Community Financial in the third quarter worth $107,000. Jefferies Group LLC bought a new stake in United Community Financial in the third quarter worth $124,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in United Community Financial in the third quarter worth $162,000. Bank of Montreal Can lifted its position in United Community Financial by 1,215.1% in the third quarter. Bank of Montreal Can now owns 16,847 shares of the savings and loans company’s stock worth $162,000 after buying an additional 15,566 shares during the last quarter. Finally, Globeflex Capital L P bought a new stake in United Community Financial in the third quarter worth $175,000. Institutional investors own 62.08% of the company’s stock.

Shares of NASDAQ:UCFC traded up $0.05 on Wednesday, hitting $9.64. 8,711 shares of the company’s stock were exchanged, compared to its average volume of 100,679. The company has a current ratio of 0.97, a quick ratio of 0.93 and a debt-to-equity ratio of 0.31. The company has a market cap of $479.39 million, a price-to-earnings ratio of 13.03 and a beta of 0.59. United Community Financial Corp has a 12 month low of $8.49 and a 12 month high of $11.98.

United Community Financial (NASDAQ:UCFC) last posted its earnings results on Wednesday, January 23rd. The savings and loans company reported $0.18 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.20 by ($0.02). The business had revenue of $29.08 million for the quarter, compared to analyst estimates of $29.03 million. United Community Financial had a return on equity of 12.34% and a net margin of 27.75%. As a group, equities research analysts predict that United Community Financial Corp will post 0.81 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, February 15th. Shareholders of record on Monday, February 4th were given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 2.90%. The ex-dividend date of this dividend was Friday, February 1st. United Community Financial’s payout ratio is 37.84%.

Several analysts have recently weighed in on the company. ValuEngine upgraded United Community Financial from a “sell” rating to a “hold” rating in a research report on Tuesday, November 13th. BidaskClub upgraded United Community Financial from a “sell” rating to a “hold” rating in a research report on Tuesday, December 18th. Zacks Investment Research downgraded United Community Financial from a “hold” rating to a “sell” rating in a research report on Saturday, January 19th. Finally, Boenning Scattergood reiterated a “hold” rating on shares of United Community Financial in a research report on Friday, January 25th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $12.00.

COPYRIGHT VIOLATION WARNING: This story was reported by Fairfield Current and is the property of of Fairfield Current. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.fairfieldcurrent.com/news/2019/03/13/vanguard-group-inc-has-20-92-million-position-in-united-community-financial-corp-ucfc.html.

United Community Financial Company Profile

United Community Financial Corp. operates as the holding company for Home Savings Bank that provides consumer and business banking services. The company offers various deposit instruments, including checking accounts, regular savings accounts, money market accounts, individual retirement accounts, and certificates of deposit.

See Also: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding UCFC?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Community Financial Corp (NASDAQ:UCFC).

Institutional Ownership by Quarter for United Community Financial (NASDAQ:UCFC)

Receive News & Ratings for United Community Financial Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for United Community Financial and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Trillium Therapeutics (TRIL) Price Target Cut to $4.00

Two Sigma Investments LP acquired a new position in shares of Trillium Therapeutics during the 4th quarter worth approximately $35,000. Finally …

Trillium Therapeutics logoTrillium Therapeutics (NASDAQ:TRIL) (TSE:TR) had its target price decreased by research analysts at HC Wainwright from $10.00 to $4.00 in a report released on Wednesday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 479.71% from the company’s current price.

TRIL has been the topic of several other research reports. ValuEngine cut Trillium Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 25th. Zacks Investment Research cut Trillium Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 21st. Finally, Cowen reiterated a “buy” rating on shares of Trillium Therapeutics in a report on Thursday, December 20th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $4.67.

Trillium Therapeutics stock traded up $0.02 during mid-day trading on Wednesday, hitting $0.69. The stock had a trading volume of 2,800 shares, compared to its average volume of 440,227. The stock has a market cap of $10.15 million, a price-to-earnings ratio of -0.20 and a beta of 2.58. Trillium Therapeutics has a 12 month low of $0.65 and a 12 month high of $8.40. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.01.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in shares of Trillium Therapeutics by 164.0% during the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 16,541 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Trillium Therapeutics during the 4th quarter worth approximately $43,000. Two Sigma Investments LP acquired a new position in shares of Trillium Therapeutics during the 4th quarter worth approximately $35,000. Finally, Morgan Stanley increased its position in shares of Trillium Therapeutics by 25.2% during the 3rd quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after purchasing an additional 71,860 shares during the last quarter. Hedge funds and other institutional investors own 45.98% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Featured Story: Convertible Shares

The Fly

Receive News & Ratings for Trillium Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Trillium Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Sientra (SIEN) Price Target Cut to $18.00

Two Sigma Investments LP acquired a new position in Sientra in the fourth quarter valued at about $1,530,000. Finally, Northern Trust Corp grew its …

Sientra logoSientra (NASDAQ:SIEN) had its price objective cut by research analysts at Leerink Swann from $22.00 to $18.00 in a report issued on Wednesday. Leerink Swann’s price target indicates a potential upside of 100.89% from the company’s previous close.

Other equities analysts have also issued research reports about the company. BidaskClub lowered Sientra from a “hold” rating to a “sell” rating in a research note on Tuesday, November 13th. Zacks Investment Research raised Sientra from a “sell” rating to a “hold” rating in a report on Friday, November 16th. Maxim Group raised Sientra from a “hold” rating to a “buy” rating in a report on Wednesday, December 19th. ValuEngine cut Sientra from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. Finally, William Blair lowered shares of Sientra from an “outperform” rating to a “market perform” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. Sientra presently has an average rating of “Buy” and a consensus target price of $22.11.

NASDAQ:SIEN traded down $2.42 during mid-day trading on Wednesday, hitting $8.96. 1,194,419 shares of the stock traded hands, compared to its average volume of 575,275. Sientra has a 52 week low of $8.79 and a 52 week high of $26.79. The company has a market capitalization of $302.01 million, a price-to-earnings ratio of -3.18 and a beta of -0.03. The company has a current ratio of 2.77, a quick ratio of 2.34 and a debt-to-equity ratio of 0.36.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.19). Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The firm had revenue of $19.02 million for the quarter, compared to analyst estimates of $18.87 million. As a group, equities analysts forecast that Sientra will post -3.05 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of SIEN. Millennium Management LLC raised its position in Sientra by 117.6% during the 4th quarter. Millennium Management LLC now owns 966,106 shares of the medical instruments supplier’s stock worth $12,279,000 after buying an additional 522,153 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Sientra in the 3rd quarter worth approximately $3,767,000. Bank of New York Mellon Corp grew its position in Sientra by 170.1% in the second quarter. Bank of New York Mellon Corp now owns 218,367 shares of the medical instruments supplier’s stock valued at $4,261,000 after acquiring an additional 137,531 shares during the period. Two Sigma Investments LP acquired a new position in Sientra in the fourth quarter valued at about $1,530,000. Finally, Northern Trust Corp grew its stake in Sientra by 74.2% in the second quarter. Northern Trust Corp now owns 270,559 shares of the medical instruments supplier’s stock valued at $5,278,000 after purchasing an additional 115,283 shares in the last quarter. 84.75% of the stock is currently owned by institutional investors.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading: What is the float in trading stocks?

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sientra and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Aptose Biosciences (APTO) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Finally, Renaissance Technologies LLC increased its holdings in Aptose Biosciences by 1,130.9% in the 3rd quarter. Renaissance Technologies LLC …

Aptose Biosciences logoAptose Biosciences (NASDAQ:APTO) (TSE:APS) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01), Morningstar.com reports.

NASDAQ APTO opened at $1.74 on Wednesday. Aptose Biosciences has a one year low of $1.57 and a one year high of $4.55. The stock has a market capitalization of $66.66 million, a P/E ratio of -3.35 and a beta of 1.81.

Several equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a report on Thursday, December 13th. Roth Capital restated a “buy” rating on shares of Aptose Biosciences in a report on Wednesday, December 12th. B. Riley assumed coverage on Aptose Biosciences in a report on Friday, November 16th. They set a “buy” rating and a $5.00 price target for the company. Finally, Citigroup assumed coverage on Aptose Biosciences in a report on Friday, January 25th. They set an “outperform” rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $5.79.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Noven Financial Group Inc. bought a new stake in Aptose Biosciences in the 4th quarter worth about $27,000. Geode Capital Management LLC bought a new stake in Aptose Biosciences in the 4th quarter worth about $33,000. Citadel Advisors LLC bought a new stake in Aptose Biosciences in the 3rd quarter worth about $125,000. Patriot Financial Group Insurance Agency LLC increased its holdings in Aptose Biosciences by 11.4% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after buying an additional 5,890 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Aptose Biosciences by 1,130.9% in the 3rd quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after buying an additional 168,501 shares in the last quarter. Institutional investors own 3.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Aptose Biosciences (APTO) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS” was first reported by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.fairfieldcurrent.com/news/2019/03/13/aptose-biosciences-apto-releases-quarterly-earnings-results-misses-estimates-by-0-01-eps.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also: What are different types of coverage ratios?

Earnings History for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptose Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Randgold Resources (GOLD) Stock Rating Upgraded by Desjardins

Renaissance Technologies LLC now owns 2,028,300 shares of the basic materials company’s stock worth $143,097,000 after purchasing an …

Randgold Resources logoRandgold Resources (NASDAQ:GOLD) was upgraded by stock analysts at Desjardins from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, The Fly reports.

A number of other research analysts also recently commented on the company. CIBC upgraded Randgold Resources from a “neutral” rating to an “outperform” rating in a research note on Wednesday, January 2nd. Macquarie upgraded Randgold Resources from a “neutral” rating to an “outperform” rating in a research note on Monday, January 28th. BidaskClub upgraded Randgold Resources from a “hold” rating to a “buy” rating in a research note on Tuesday, December 11th. Barclays assumed coverage on Randgold Resources in a research note on Wednesday, January 9th. They set an “overweight” rating for the company. Finally, Raymond James set a $17.00 price target on Randgold Resources and gave the stock a “market perform” rating in a research note on Wednesday, January 23rd. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $40.47.

Shares of NASDAQ GOLD opened at $13.23 on Wednesday. Randgold Resources has a one year low of $9.53 and a one year high of $14.18. The stock has a market capitalization of $15.39 billion, a price-to-earnings ratio of 4.53 and a beta of -0.23.

Randgold Resources (NASDAQ:GOLD) last issued its earnings results on Wednesday, February 13th. The basic materials company reported $0.06 EPS for the quarter, meeting analysts’ consensus estimates of $0.06. Randgold Resources had a return on equity of 6.16% and a net margin of 21.82%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the previous year, the company posted $0.22 earnings per share. The business’s quarterly revenue was down 14.5% compared to the same quarter last year. As a group, equities research analysts forecast that Randgold Resources will post 2.62 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GOLD. Hsbc Holdings PLC lifted its position in shares of Randgold Resources by 27.1% during the 3rd quarter. Hsbc Holdings PLC now owns 55,475 shares of the basic materials company’s stock worth $3,914,000 after purchasing an additional 11,825 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Randgold Resources by 11.9% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 16,171 shares of the basic materials company’s stock worth $1,141,000 after purchasing an additional 1,719 shares during the last quarter. Credit Suisse AG lifted its position in shares of Randgold Resources by 43.2% during the 3rd quarter. Credit Suisse AG now owns 443,807 shares of the basic materials company’s stock worth $31,311,000 after purchasing an additional 133,961 shares during the last quarter. Schroder Investment Management Group lifted its position in shares of Randgold Resources by 45.4% during the 3rd quarter. Schroder Investment Management Group now owns 186,191 shares of the basic materials company’s stock worth $13,135,000 after purchasing an additional 58,156 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Randgold Resources by 69.1% during the 3rd quarter. Renaissance Technologies LLC now owns 2,028,300 shares of the basic materials company’s stock worth $143,097,000 after purchasing an additional 828,938 shares during the last quarter. Institutional investors own 39.71% of the company’s stock.

Randgold Resources Company Profile

Randgold Resources Ltd. engages in the exploration and development of gold deposits. Its projects include the following: Loulo-Gounkoto complex, Morila gold mine, Tongon gold mine, Kibali gold mine, and Massawa. The company was founded in August 1995 and is headquartered in St. Helier, the United Kingdom.

Featured Story: Quiet Period

The Fly

Analyst Recommendations for Randgold Resources (NASDAQ:GOLD)

Receive News & Ratings for Randgold Resources Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Randgold Resources and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts